Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Haematological Malignancies Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow-up.
Jeff Porter Sharman, Miklos Egyed, Wojciech Jurczak, et al.
The study authors conclude that with a median follow-up of almost four years, the efficacy and safety of acalabrutinib ± obinutuzumab and acalabrutinib monotherapy was maintained. There was an increase in CR since the interim analysis (from 21% to 27% [A+O] and from 7% to 11% [A]) and low rates of discontinuation.
Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
Matthew J. Matasar, Marcelo Capra, Muhit Özcan, et al.
The study authors conclude that copanlisib + rituximab demonstrated superior efficacy compared to rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma /MZL). The combination had a manageable safety profile, consistent with copanlisib and rituximab as monotherapy. According to the authors, copanlisib is the first PI3K inhibitor to be safely combined with rituximab in relapsed FL/MZL, representing a potential new therapeutic option. Clinical trial information: NCT02367040
Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.
Nilanjan Ghosh, Gilles A. Salles, Izidore S. Lossos, et al.
The study authors conclude that the triple combination is efficacious in patients with relapsed/refractory follicular lymphoma. The data from the final analysis suggest a potential for improved outcomes versus the Obinutuzumab-lenalidomide doublet. Clinical trial information: NCT02631577
Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
Catherine S. Magid Diefenbach, Pau Abrisqueta, Eva Gonzalez-Barca, et al.
The study authors conclude that their study demonstrates a tolerable safety profile. Pola-R-Len shows promising activity in a difficult-to-treat R/R DLBCL population. This is particularly observed in patients achieving CR, a large proportion of whom remain in remission at the cutoff date. Clinical trial information: NCT02600897
Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Johannes Düll, Kami J. Maddocks, Eva Gonzalez-Barca, et al.
The study authors conclude that the combination with tafasitamab + lenalidomide followed by tafasitamab monotherapy provided durable responses in patients with R/R DLBCL not eligible for ASCT. A manageable safety profile was observed. This indicates the potential of tafasitamab + lenalidomide in this patient population followed by extended tafasitamab monotherapy in achieving prolonged remission and survival benefit, especially at first relapse. Clinical trial information: NCT02399085
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
Jia Ruan, Jasmine M. Zain, Brett Palmer, et al.
The study authors provide the first demonstration that a chemo-free biologic combination of romidepsin and lenalidomide is a feasible and effective initial treatment for PTCL patients who are not candidates for cytotoxic chemotherapy. Clinical trial information: NCT02232516
Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).
Caron A. Jacobson, Julio C. Chavez, Alison Sehgal, et al.
The study authors conclude that axicabtagene ciloleucel showed in this population with high-risk disease with POD24 iNHL a high rate of durable responses in patients. Efficacy results, as well as safety and pharmacological profiles, appeared largely comparable between groups, except for the progression-free survival rates. Clinical trial information: NCT03105336
Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.
Bijal D. Shah, Caron A. Jacobson, Scott Solomon, et al.
The study authors conclude that PBCAR0191 has demonstrated dose and LD-dependent cell expansion kinetics with encouraging anti-tumor activity. They note, that host-versus-graft rejection may have a role in depth and durability of response. Finally, CR rates with this allogeneic, off-the-shelf CD19-targeting CAR-T product are preliminarily comparable to those observed with autologous CAR T in this population. Clinical trial information: NCT03666000
Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.
Joshua W. Keegan, Frank Borriello, Stacey M. Fernandes, et al.
The study authors demonstrate for the first time that peripheral blood mononuclear cells from CLL patients can be converted into SUPLEXA cells (a 300-fold expansion of NK cells, CD8+ T cells, NKT cells, and TCRγδ T cells). This is achieved despite low numbers of normal immune cells at baseline and the known immunologic impairment present in CLL patients. The authors stress, that importantly, SUPLEXA cells derived from CLL patients acquire potent tumor killing activity that is indistinguishable from SUPLEXA cells prepared from NHVs. They conclude, that these findings support the feasibility of converting PBMCs from CLL patients with low percentages of NK and T cells into an autologous cellular therapy for cancer.
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
Michael Roost Clausen, Pieternella Lugtenburg, Martin Hutchings, et al.
The study authors conclude that with longer follow-up, subcutaneous epcoritamab - a CD20xCD3 bispecific antibody that induces T-cell–mediated killing of CD20–positive malignant B-cells - demonstrated substantial single-agent activity, inducing deep and durable clinically meaningful responses, with a consistent safety profile without severe (grade ≥3) CRS events, no febrile neutropenia, and limited neurotoxicity. Clinical trial information: NCT03625037
Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).
Carmelo Carlo-Stella, Martin Hutchings, Fritz C. Offner, et al.
Glofitamab is a T-cell-engaging, bispecific, full-length antibody. It allows bivalent binding to CD20 (B-cells), and monovalent binding to CD3 (T-cells). The study authors demonstrated with updated data for glofitamab monotherapy step-up dosing higher preliminary response rates than previously reported in patients with R/R NHL who have failed multiple lines of therapy. Cytokine release syndrome was mostly manageable, of low grade, and confined to the first cycle of treatment. Clinical trial information: NCT03075696
Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).
L Elizabeth Budde, Nilanjan Ghosh, Julio C. Chavez, et al.
The study authors show with their data, that M-Pola has an acceptable safety profile, with no Gr ≥2 cytokine release syndrome observed. It has promising efficacy in patients with R/R NHL with predominantly aggressive disease. Clinical trial information: NCT03671018